Core Points - A class action lawsuit has been filed against Zenas BioPharma, Inc. for alleged securities fraud and unlawful business practices [2][4] - Investors who purchased Zenas securities during its initial public offering (IPO) are encouraged to join the class action by contacting Pomerantz LLP [1][2] - Zenas conducted its IPO on September 13, 2024, selling approximately 13.235 million shares at $17.00 per share, but its stock price has significantly declined since then [4] Company Information - Zenas BioPharma, Inc. is facing legal scrutiny due to claims of misleading statements regarding its financial stability post-IPO [2][4] - The company stated it could fund operations for "at least" the next twelve months, contrary to earlier claims of twenty-four months in its IPO registration [4] Legal Context - The deadline for investors to request appointment as Lead Plaintiff in the class action is June 16, 2025 [2] - Pomerantz LLP is recognized for its expertise in corporate and securities class litigation, having a long history of advocating for victims of securities fraud [5]

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas BioPharma’s September 2024 initial public offering (“IPO” or the “Offering”), of the important June 16, 2025 lead plaintiff deadline in the securities class action first filed by the fi ...

Core Viewpoint - A class action securities lawsuit has been filed against Zenas BioPharma, Inc. due to alleged securities fraud affecting investors who purchased shares during the company's September 2024 initial public offering [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors adversely affected by alleged securities fraud related to Zenas BioPharma's IPO [2]. - The complaint alleges that Zenas BioPharma materially overstated its ability to fund operations using existing cash and expected net proceeds from the IPO, leading to false and misleading public statements [3]. Group 2: Investor Information - Investors who suffered losses in Zenas BioPharma during the relevant time frame have until June 16, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securing compensation for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

WASHINGTON, April 24, 2025 (GLOBE NEWSWIRE) -- Investors in Zenas BioPharma, Inc. (NASDAQ: ZBIO) who bought shares in the company’s September 2024 IPO may be eligible to participate in and lead a class action lawsuit now pending in federal court. Cohen Milstein Sellers & Toll PLLC, a nationally recognized investor rights law firm, is actively investigating claims and encouraging shareholders with significant losses to reach out now. [Click here for information about joining the class action] If you’d like t ...

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) (“Zenas” or the “Company”) securities pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with Zenas’ initial public offering held on September 13, 2024 (the “IPO”), charging the Company, certain senior executives and directors, and the underwriters ...

NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration sta ...

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to Zenas BioPharma’s registration statement issued in connection with Zenas BioPharma’s initial public offering (the “IPO”) held on or around September 13, 2024, and were damaged thereby, have until June 16, 2025 to seek appointment as lead plaintiff of the Zenas BioPharma class action lawsuit. Capti ...

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zenas BioPharma, Inc. (NASDAQ: ZBIO). Shareholders who purchased shares of ZBIO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/zenas-biopharma-inc-loss-submission-form/?id=144444&from=3  CLASS PERIOD: T ...

WASHINGTON, April 22, 2025 (GLOBE NEWSWIRE) -- Cohen Milstein Sellers & Toll PLLC is investigating potential securities fraud claims on behalf of investors in Zenas BioPharma, Inc. (NASDAQ:ZBIO) who acquired shares in the company's September 2024 initial public offering ("IPO"). The firm urges affected investors to contact the firm promptly to discuss their legal rights and recovery options. [Click here for information about joining the class action] Or investors should reach out to Molly J. Bowen, a partne ...

NEW YORK, April 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. ("Zenas BioPharma, Inc." or the "Company") (NASDAQ: ZBIO) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and/or traceable to the registration statemen ...